Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing cancer immunotherapies in the United States. The company develops various programs targeting immuno-oncology pathways, including AB928, a dual adenosine receptor antagonist, which is in a Phase I/Ib clinical trial; and AB122, an anti-PD-1 antibody that is in Phase I clinical trial.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone510-694-6200
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$8.35 million
Profitability
Miscellaneous
Employees108
Next Earnings Date11/14/2019 (Estimated)
OptionableOptionable
Arcus Biosciences (NYSE:RCUS) Frequently Asked Questions
What is Arcus Biosciences' stock symbol?
Arcus Biosciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "RCUS."
How were Arcus Biosciences' earnings last quarter?
Arcus Biosciences Inc (NYSE:RCUS) issued its quarterly earnings results on Tuesday, August, 6th. The company reported ($0.64) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.40) by $0.24. The company earned $1.75 million during the quarter, compared to analysts' expectations of $4.54 million. Arcus Biosciences had a negative return on equity of 30.67% and a negative net margin of 736.31%. View Arcus Biosciences' Earnings History.
When is Arcus Biosciences' next earnings date?
What price target have analysts set for RCUS?
4 brokers have issued 1-year target prices for Arcus Biosciences' stock. Their forecasts range from $15.00 to $22.00. On average, they anticipate Arcus Biosciences' share price to reach $19.00 in the next year. This suggests a possible upside of 134.0% from the stock's current price. View Analyst Price Targets for Arcus Biosciences.
What is the consensus analysts' recommendation for Arcus Biosciences?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arcus Biosciences in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Arcus Biosciences.
Has Arcus Biosciences been receiving favorable news coverage?
Press coverage about RCUS stock has been trending very negative on Thursday, InfoTrie reports. The research group ranks the sentiment of news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Arcus Biosciences earned a media sentiment score of -3.2 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near term. View News Stories for Arcus Biosciences.
Are investors shorting Arcus Biosciences?
Arcus Biosciences saw a increase in short interest in September. As of September 30th, there was short interest totalling 1,810,000 shares, an increase of 9.0% from the August 30th total of 1,660,000 shares. Based on an average daily trading volume, of 195,900 shares, the short-interest ratio is currently 9.2 days. Approximately 6.6% of the company's shares are sold short. View Arcus Biosciences' Current Options Chain.
Who are some of Arcus Biosciences' key competitors?
Some companies that are related to Arcus Biosciences include Heron Therapeutics (HRTX), Nabriva Therapeutics (NBRV), Supernus Pharmaceuticals (SUPN), Ironwood Pharmaceuticals (IRWD), Eidos Therapeutics (EIDX), Madrigal Pharmaceuticals (MDGL), Opko Health (OPK), BELLUS Health (BLUSF), Turning Point Therapeutics (TPTX), Enanta Pharmaceuticals (ENTA), Radius Health (RDUS), Zymeworks (ZYME), Innoviva (INVA), Esperion Therapeutics (ESPR) and ArQule (ARQL).
What other stocks do shareholders of Arcus Biosciences own?
Who are Arcus Biosciences' key executives?
Arcus Biosciences' management team includes the folowing people:
- Dr. Terry Rosen Ph.D., Co-Founder, Chairman & CEO (Age 59)
- Dr. Juan Carlos Jaen, Co-Founder, Pres & Director (Age 61)
- Mr. Steven Chan, Consultant (Age 47)
- Ms. Rekha Hemrajani, Chief Operating & Financial Officer (Age 49)
- Dr. Stephen Young Ph.D., VP of Technology (Age 50)
When did Arcus Biosciences IPO?
(RCUS) raised $99 million in an initial public offering (IPO) on Thursday, March 15th 2018. The company issued 7,100,000 shares at $13.00-$15.00 per share. Citigroup, Goldman Sachs and Leerink Partners acted as the underwriters for the IPO.
How do I buy shares of Arcus Biosciences?
Shares of RCUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Arcus Biosciences' stock price today?
One share of RCUS stock can currently be purchased for approximately $8.12.
How big of a company is Arcus Biosciences?
Arcus Biosciences has a market capitalization of $372.29 million and generates $8.35 million in revenue each year. The company earns $-49,590,000.00 in net income (profit) each year or ($1.43) on an earnings per share basis. Arcus Biosciences employs 108 workers across the globe.View Additional Information About Arcus Biosciences.
What is Arcus Biosciences' official website?
How can I contact Arcus Biosciences?
Arcus Biosciences' mailing address is 3928 Point Eden Way, Hayward CA, 94545. The company can be reached via phone at 510-694-6200 or via email at [email protected]
MarketBeat Community Rating for Arcus Biosciences (NYSE RCUS)
MarketBeat's community ratings are surveys of what our community members think about Arcus Biosciences and other stocks. Vote "Outperform" if you believe RCUS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RCUS will underperform the S&P 500 over the long term. You may vote once every thirty days.
